Biocides with glutaraldehyde: new obligations for manufacturers and industrial users in the EU

Key data

Manufacturers and distributors of industrial disinfectants and preservatives based on glutaraldehyde have new rules of the game throughout the EU. The Commission Implementing Regulation (EU) 2026/2053, in force since 10 September 2026, grants a Union authorization for the family of biocides «Glutaraldehyde formulations», which unifies the conditions for marketing in all Member States.

Until now, authorizations for these products could vary from one country to another. With this regulation, the conditions for labeling, composition and use are harmonized at European level, which simplifies access to the single market but also imposes specific requirements that companies must comply with without exception.

What does this regulation establish?

Commission Implementing Regulation (EU) 2026/2053 is based on Regulation (EU) No 528/2012 on biocides and establishes the following key elements:

• Single Union authorization for the family of products «Glutaraldehyde formulations», valid in all Member States without the need for additional national authorizations.
• Harmonized conditions for composition, labeling and use that all products in this family must comply with in order to be marketed.
• Obligation to review safety data sheets (SDS) by sectors using glutaraldehyde as a disinfectant or preservative.
• Adaptation period for products already marketed before the regulation enters into force.
• Consequence of non-compliance: withdrawal from the market of products that do not meet the authorization conditions.

Glutaraldehyde is a chemical compound widely used as a high-level disinfectant in healthcare and veterinary settings, as well as a preservative in industrial processes. The unified authorization facilitates its cross-border marketing, but requires that all products in the family comply with exactly the same technical and safety standards.

Economic and operational impact

The impact of this regulation is not primarily financial in terms of fees or quantified penalties in the text, but rather operational and market access. Companies that fail to adapt their products in time face the most serious possible consequence: withdrawal of affected products from the market, with the economic cost that this entails in immobilized stock, loss of sales and possible customer claims.

For companies operating in several EU countries, the single authorization also represents an opportunity: it eliminates the need to manage multiple national authorizations, reducing administrative burden and compliance costs in the long term.

Who does it affect?

• Manufacturers of biocides with glutaraldehyde that market products in the EU: must verify that their formulations comply with the conditions of the authorization granted.
• Distributors and marketers of these products: responsible for ensuring that the products they place on the market carry the correct labeling.
• Healthcare sector (hospitals, clinics, health centers): professional users who use glutaraldehyde for high-level disinfection of medical instruments.
• Veterinary sector: clinics and facilities that use these products as disinfectants.
• Industrial sector: companies that use glutaraldehyde as a preservative in manufacturing processes, water treatment or oil and gas industry.
• Procurement and safety managers in user companies: must verify that the products they purchase have current authorization and correct labeling.

Practical example

A Spanish company manufacturing disinfectant solutions for the hospital sector that markets a glutaraldehyde-based product in Spain, France and Germany must act as follows:

1. Verify that its formulation falls within the family «Glutaraldehyde formulations» authorized by Regulation (EU) 2026/2053.
2. Review the current labeling of its products and update it to reflect the harmonized conditions of the Union authorization, valid for all three countries without additional procedures per country.
3. Update the safety data sheets (SDS) of all affected products.
4. Review the recommended use procedures in its technical data sheets for hospital customers.
5. Ensure that stock already marketed is adapted within the established period to avoid withdrawal from the market.

The direct benefit: with a single Union authorization, this company can operate in all 27 EU markets without managing separate national authorizations, which significantly reduces administrative burden.

What should companies do now?

1. Identify affected products: review the catalog of products containing glutaraldehyde and determine which ones fall within the authorized «Glutaraldehyde formulations» family.
2. Review labeling: compare current labeling with the specific requirements established in Regulation (EU) 2026/2053 and update as necessary.
3. Update safety data sheets (SDS): the healthcare, veterinary and industrial sectors must review and update their SDS to reflect the new regulatory requirements.
4. Review internal use procedures: verify that the product application protocols in plant, operating room or veterinary facility are consistent with the authorized conditions of use.
5. Consult the adaptation period for products already marketed before the regulation enters into force and plan the transition to avoid withdrawal from the market.
6. Inform the distribution chain: manufacturers must communicate changes to distributors and professional customers to ensure compliance throughout the chain.

The risk of not acting is clear: products that do not comply with the authorization conditions may be withdrawn from the market, with the economic and reputational impact that this entails.

Official source

Consult complete regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202602053